Perfusion in the Tissue Surrounding Pancreatic Cancer and the Patient’s Prognosis

Table 1

Background information for patients enrolled.

Number	Sex (M/F)	Age (age)	Survival days from date PCT performed	TNM	Stage
1	M	78	57	T4N2M1	IVb
2	M	61	298	T4N0M0	IVa
3	M	59	360	T4N3M1	IVb
4	F	78	80	T3N1M1	IVb
5	M	36	167	T3N0M1	IVb
6	F	63	138	T4N2M0	IVb
7	F	65	662	T4N1M0	IVa
8	M	61	82	T4N0M1	IVb
9	M	49	290	T4N0M0	IVa
10	M	55	166	T4N0M1	IVb
11	F	67	386	T4N0M0	IVa
12	M	64	914	T4N1M0	IVa
13	M	66	415	T4N0M0	IVa
14	M	65	730	T4N0M1	IVb
15	M	46	164	T4N0M0	IVa
16	F	66	490	T3N0M1	IVb
17	M	46	336	T4N0M0	IVa
	12/5	63.0 ± 11.1	298 ± 246

Figures (median ± SD) for age and survival days from date perfusion CT (PCT) performed appear at the bottom of each column.